Treace Medical Concepts Q2 2024 GAAP EPS $(0.34) Misses $(0.29) Estimate, Sales $44.455M Beat $43.000M Estimate
Portfolio Pulse from Benzinga Newsdesk
Treace Medical Concepts (NASDAQ:TMCI) reported Q2 2024 GAAP EPS of $(0.34), missing the $(0.29) estimate, but sales of $44.455M beat the $43.000M estimate. EPS decreased by 70% YoY, while sales increased by 5.96% YoY.
August 06, 2024 | 10:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Treace Medical Concepts reported Q2 2024 GAAP EPS of $(0.34), missing the $(0.29) estimate, but sales of $44.455M beat the $43.000M estimate. EPS decreased by 70% YoY, while sales increased by 5.96% YoY.
The significant miss on EPS and the large YoY decrease in EPS are likely to negatively impact the stock price in the short term, despite the sales beat.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100